US Patent Issued to University of Maryland, Baltimore, The United States of America as represented by the Department of Veterans Affairs on Sept. 15 for "Non-catalytic substrate-selective p38Alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof" (Maryland Inventors)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,734,176, issued on Sept. 15, was assigned to University of Maryland, Baltimore (Baltimore) and The United States of America as represented by the Department of Veterans Affairs (Washington).

"Non-catalytic substrate-selective p38Alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof" was invented by Paul S. Shapiro (Baltimore), Alexander D. Mackerell Jr. (Baltimore) and Jeffrey D. Hasday (Timonium, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compounds that inhibit p38Alpha MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or...